euvascor 10 mg/10 mg
anpharm przedsiebiorstwo farmaceutyczne s.a., poľsko - atorvastatín a perindopril - 58 - hypotensiva
euvascor 40 mg/10 mg
anpharm przedsiebiorstwo farmaceutyczne s.a., poľsko - atorvastatín a perindopril - 58 - hypotensiva
euvascor 20 mg/5 mg
anpharm przedsiebiorstwo farmaceutyczne s.a., poľsko - atorvastatín a perindopril - 58 - hypotensiva
atorvastatin xantis 80 mg
xantis pharma limited, cyprus - atorvastatín - 31 - hypolipidaemica
atorvastatin xantis 40 mg
xantis pharma limited, cyprus - atorvastatín - 31 - hypolipidaemica
atorvastatin xantis 20 mg
xantis pharma limited, cyprus - atorvastatín - 31 - hypolipidaemica
atorvastatin xantis 10 mg
xantis pharma limited, cyprus - atorvastatín - 31 - hypolipidaemica
rupatadine mylan 10 mg tablety
mylan ireland limited, Írsko - rupatadín - 24 - antihistaminica, histamin
symkevi
vertex pharmaceuticals (ireland) limited - tezacaftor, ivacaftor - cystická fibróza - ostatné produkty dýchacej sústavy - symkevi is indicated in a combination regimen with ivacaftor tablets for the treatment of patients with cystic fibrosis (cf) aged 6 years and older who are homozygous for the f508del mutation or who are heterozygous for the f508del mutation and have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (cftr) gene: p67l, r117c, l206w, r352q, a455e, d579g, 711+3a→g, s945l, s977f, r1070w, d1152h, 2789+5g→a, 3272 26a→g, and 3849+10kbc→t.
verzenios
eli lilly nederland b.v. - abemaciclib - neoplazmy prsníkov - antineoplastické činidlá - early breast cancerverzenios in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative, node positive early breast cancer at high risk of recurrence (see section 5. in pre or perimenopausal women, aromatase inhibitor endocrine therapy should be combined with a luteinising hormone-releasing hormone (lhrh) agonist. advanced or metastatic breast cancerverzenios is indicated for the treatment of women with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy. in pre- or perimenopausal women, the endocrine therapy should be combined with a lhrh agonist.